Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Lymphoma

  Free Subscription


Articles published in Blood

Retrieve available abstracts of 235 articles:
HTML format
Text format



Single Articles


    November 2017
  1. STEIDL C
    The ecosystem of classical Hodgkin lymphoma.
    Blood. 2017;130:2360-2361.
    PubMed     Text format    


  2. KOHNKEN R, Wen J, Mundy-Bosse B, McConnell K, et al
    Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.
    Blood. 2017 Nov 27. pii: blood-2017-09-805663. doi: 10.1182/blood-2017-09-805663
    PubMed     Text format     Abstract available


  3. LIU WR, Shipp MA
    Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
    Blood. 2017;130:2265-2270.
    PubMed     Text format     Abstract available


  4. GREEN MR
    Chromatin modifying gene mutations in follicular lymphoma.
    Blood. 2017 Nov 20. pii: blood-2017-08-737361. doi: 10.1182/blood-2017-08-737361
    PubMed     Text format     Abstract available



  5. Diffuse large B-cell lymphoma in the elderly.
    Blood. 2017;130:2235.
    PubMed     Text format    


  6. CRANE GM, Perkins AS
    Leukemic presentation of diffuse large B-cell lymphoma: an unusual pattern associated with splenic involvement.
    Blood. 2017;130:2233.
    PubMed     Text format    


  7. AMENGUAL JE, Lichtenstein R, Lue J, Sawas A, et al
    A phase I study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Blood. 2017 Nov 15. pii: blood-2017-09-806737. doi: 10.1182/blood-2017-09-806737
    PubMed     Text format     Abstract available


  8. QUESADA AE, Konoplev S
    Classical Hodgkin lymphoma arising in a patient with chronic lymphocytic leukemia (Richter syndrome).
    Blood. 2017;130:2151.
    PubMed     Text format    


  9. MOTTOK A, Jurinovic V, Farinha P, Rosenwald A, et al
    FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab-containing regimens.
    Blood. 2017 Nov 9. pii: blood-2017-08-799080. doi: 10.1182/blood-2017-08-799080.
    PubMed     Text format     Abstract available


  10. RYAN MC, Palanca-Wessels MC, Schimpf B, Gordon KA, et al
    Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.
    Blood. 2017;130:2018-2026.
    PubMed     Text format     Abstract available


    October 2017
  11. KATAOKA K, Iwanaga M, Yasunaga JI, Nagata Y, et al
    Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
    Blood. 2017 Oct 30. pii: blood-2017-01-761874. doi: 10.1182/blood-2017-01-761874
    PubMed     Text format     Abstract available


  12. FISH K, Sora RP, Schaller SJ, Longnecker R, et al
    EBV latent membrane protein 2A orchestrates p27kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice.
    Blood. 2017 Oct 26. pii: blood-2017-07-796821. doi: 10.1182/blood-2017-07-796821
    PubMed     Text format     Abstract available


  13. BARTLETT NL, Costello BA, LaPlant BR, Ansell SM, et al
    Single-Agent Ibrutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial.
    Blood. 2017 Oct 26. pii: blood-2017-09-804641. doi: 10.1182/blood-2017-09-804641
    PubMed     Text format     Abstract available


  14. LAMY T, Damaj G, Soubeyran P, Gyan E, et al
    R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL).
    Blood. 2017 Oct 23. pii: blood-2017-07-793984. doi: 10.1182/blood-2017-07-793984
    PubMed     Text format     Abstract available



  15. Genomic analysis of adult Burkitt lymphoma.
    Blood. 2017;130:1871.
    PubMed     Text format    


  16. PILERI SA
    Understanding lymphoma molecular complexity.
    Blood. 2017;130:1780-1781.
    PubMed     Text format    


  17. RUTHERFORD SC, Leonard JP
    Lymphoma "benchmark" or "bench-smudge"?
    Blood. 2017;130:1778-1779.
    PubMed     Text format    


  18. AKHTARI M, Milgrom SA, Pinnix CC, Reddy JP, et al
    Re-classifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation.
    Blood. 2017 Oct 16. pii: blood-2017-04-773838. doi: 10.1182/blood-2017-04-773838
    PubMed     Text format     Abstract available


  19. BALAKRISHNA JP, Jaffe ES
    Crystal-storing histiocytosis associated with thymic extranodal marginal zone lymphoma.
    Blood. 2017;130:1683.
    PubMed     Text format    


  20. BOBROWICZ M, Dwojak M, Pyrzynska B, Stachura J, et al
    HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
    Blood. 2017;130:1628-1638.
    PubMed     Text format     Abstract available


  21. PRO B, Advani R, Brice P, Bartlett NL, et al
    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
    Blood. 2017 Oct 3. pii: blood-2017-05-780049. doi: 10.1182/blood-2017-05-780049.
    PubMed     Text format     Abstract available


  22. CYRENNE BM, Lewis J, Weed J, Carlson K, et al
    Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Blood. 2017 Oct 2. pii: blood-2017-06-792150. doi: 10.1182/blood-2017-06-792150.
    PubMed     Text format     Abstract available


    September 2017

  23. MALT lymphoma prognostic index.
    Blood. 2017;130:1486.
    PubMed     Text format    


  24. ZHENG L, Hu S
    Philadelphia chromosome-positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse.
    Blood. 2017;130:1483.
    PubMed     Text format    


  25. PARK J, Yang J, Wenzel AT, Ramachandran A, et al
    Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).
    Blood. 2017;130:1430-1440.
    PubMed     Text format     Abstract available


  26. MALEK A, Bhagat G
    Cyclin D1-negative mantle cell lymphoma with aberrant CD3 expression.
    Blood. 2017;130:1388.
    PubMed     Text format    


  27. MARTIN P, Ruan J, Leonard JP
    The potential for chemotherapy-free strategies in mantle cell lymphoma.
    Blood. 2017 Sep 12. pii: blood-2017-05-737510. doi: 10.1182/blood-2017-05-737510
    PubMed     Text format     Abstract available


  28. CAREY CD, Gusenleitner D, Lipschitz M, Roemer MGM, et al
    Topological analysis reveals a PD-L1 associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
    Blood. 2017 Sep 11. pii: blood-2017-03-770719. doi: 10.1182/blood-2017-03-770719
    PubMed     Text format     Abstract available


  29. ASEMISSEN AM, Dierlamm J
    The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
    Blood. 2017;130:1274.
    PubMed     Text format    


  30. MOSKOWITZ AJ, Schoder H, Gavane S, Thoren KL, et al
    Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
    Blood. 2017 Sep 5. pii: blood-2017-06-788877. doi: 10.1182/blood-2017-06-788877.
    PubMed     Text format     Abstract available


    August 2017
  31. KHODARAHMI I, Ghesani N
    Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma.
    Blood. 2017;130:1174.
    PubMed     Text format    


  32. DAVIDS MS
    Targeting BCL-2 in B-cell lymphomas.
    Blood. 2017;130:1081-1088.
    PubMed     Text format     Abstract available


  33. KREMER KN, Dinkel BA, Sterner RM, Osborne DG, et al
    TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL.
    Blood. 2017;130:982-994.
    PubMed     Text format     Abstract available


  34. ESKELUND CW, Dahl C, Hansen JW, Westman M, et al
    TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
    Blood. 2017 Aug 17. pii: blood-2017-04-779736. doi: 10.1182/blood-2017-04-779736
    PubMed     Text format     Abstract available


  35. LIN RJ, Behera M, Diefenbach CS, Flowers CR, et al
    The Role of Anthracycline and Comprehensive Geriatric Assessment for Elderly Patients with Diffuse Large B-cell Lymphoma.
    Blood. 2017 Aug 16. pii: blood-2017-05-736975. doi: 10.1182/blood-2017-05-736975
    PubMed     Text format    


  36. BOUSKA A, Bi C, Lone W, Zhang W, et al
    Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets.
    Blood. 2017 Aug 11. pii: blood-2017-02-767335. doi: 10.1182/blood-2017-02-767335
    PubMed     Text format     Abstract available


  37. SALAR A, Domingo-Domenech E, Panizo C, Nicolas C, et al
    Long-term results of a phase II study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.
    Blood. 2017 Aug 11. pii: blood-2017-07-795302. doi: 10.1182/blood-2017-07-795302
    PubMed     Text format    


  38. OKONKWO L, Jaffe ES
    Intravascular large cell lymphoma of NK/T-cell type, EBV positive.
    Blood. 2017;130:837.
    PubMed     Text format    


  39. NAM AS, Tam W
    An intrasinusoidal extracavitary variant of primary effusion lymphoma.
    Blood. 2017;130:836.
    PubMed     Text format    


  40. WEIGERT O, Weinstock DM
    The promises and challenges of using gene mutations for patient stratification in follicular lymphoma.
    Blood. 2017 Aug 7. pii: blood-2017-07-737353. doi: 10.1182/blood-2017-07-737353.
    PubMed     Text format     Abstract available


  41. CRUMP M, Neelapu SS, Farooq U, Van Den Neste E, et al
    Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
    Blood. 2017 Aug 3. pii: blood-2017-03-769620. doi: 10.1182/blood-2017-03-769620.
    PubMed     Text format     Abstract available


  42. CARTRON G, Watier H
    Obinutuzumab: what is there to learn from clinical trials?
    Blood. 2017;130:581-589.
    PubMed     Text format     Abstract available


    July 2017
  43. TSUYAMA N, Sakata S, Baba S, Mishima Y, et al
    BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
    Blood. 2017;130:489-500.
    PubMed     Text format     Abstract available


  44. CONNORS JM, Ansell SM, Fanale M, Park SI, et al
    Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced stage classical Hodgkin lymphoma.
    Blood. 2017 Jul 21. pii: blood-2017-05-784678. doi: 10.1182/blood-2017-05-784678
    PubMed     Text format    



  45. Predicting transformation of follicular lymphoma.
    Blood. 2017;130:383.
    PubMed     Text format    


  46. GONG S, Hijiya N
    Classical Hodgkin lymphoma and Castleman disease: a rare morphologic combination.
    Blood. 2017;130:381.
    PubMed     Text format    


  47. FEHNIGER TA
    CD70 turns on NK cells to attack lymphoma.
    Blood. 2017;130:238-239.
    PubMed     Text format    


  48. CABANILLAS F, Rivera N
    Check this checkpoint inhibitor in lymphoma.
    Blood. 2017;130:234-235.
    PubMed     Text format    


  49. ERDMANN T, Klener P, Lynch JT, Grau M, et al
    Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
    Blood. 2017;130:310-322.
    PubMed     Text format     Abstract available


  50. THIEBLEMONT C, Cascione L, Conconi A, Kiesewetter B, et al
    A MALT lymphoma prognostic index generated from the dataset of the IELSG-19 prospective clinical trial.
    Blood. 2017 Jul 18. pii: blood-2017-03-771915. doi: 10.1182/blood-2017-03-771915
    PubMed     Text format     Abstract available


  51. WOODS DM, Woan KV, Cheng F, Sodre AL, et al
    T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model.
    Blood. 2017;130:146-155.
    PubMed     Text format     Abstract available


  52. CASASNOVAS RO, Ysebaert L, Thieblemont C, Bachy E, et al
    A FDG-PET driven consolidation strategy in diffuse large B-cell lymphoma: Final results of a randomized phase II study.
    Blood. 2017 Jul 12. pii: blood-2017-02-766691. doi: 10.1182/blood-2017-02-766691
    PubMed     Text format     Abstract available


  53. SZYDLOWSKI M, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Derezinska E, et al
    Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
    Blood. 2017 Jul 11. pii: blood-2017-01-760702. doi: 10.1182/blood-2017-01-760702
    PubMed     Text format     Abstract available


    June 2017
  54. NARITA T, Ishida T, Ito A, Masaki A, et al
    Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
    Blood. 2017 Jun 23. pii: blood-2016-09-741983. doi: 10.1182/blood-2016-09-741983
    PubMed     Text format     Abstract available


  55. HAVRANEK O, Xu J, Kohrer S, Wang Z, et al
    Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
    Blood. 2017 Jun 23. pii: blood-2016-10-747303. doi: 10.1182/blood-2016-10-747303
    PubMed     Text format     Abstract available


  56. CHIN CK, Cheah CY
    How I treat patients with aggressive lymphoma at high risk of CNS relapse.
    Blood. 2017 Jun 13. pii: blood-2017-03-737460. doi: 10.1182/blood-2017-03-737460
    PubMed     Text format     Abstract available


  57. FRIEDBERG JW
    How I treat "Double Hit" lymphoma.
    Blood. 2017 Jun 9. pii: blood-2017-04-737320. doi: 10.1182/blood-2017-04-737320.
    PubMed     Text format     Abstract available


  58. CHRISTIAN B
    Checkpoint inhibition in CNS lymphoma.
    Blood. 2017;129:3045-3046.
    PubMed     Text format    


  59. ZHANG H, Chen Z, Miranda RN, Medeiros LJ, et al
    Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia.
    Blood. 2017 Jun 7. pii: blood-2017-02-767293. doi: 10.1182/blood-2017-02-767293.
    PubMed     Text format     Abstract available


    May 2017
  60. GILL K
    CD5-negative mantle cell lymphoma of the breast.
    Blood. 2017;129:2950.
    PubMed     Text format    


  61. SCHMIDT J, Ramis-Zaldivar JE, Nadeu F, Gonzalez-Farre B, et al
    Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation.
    Blood. 2017 May 22. pii: blood-2017-03-776278. doi: 10.1182/blood-2017-03-776278
    PubMed     Text format     Abstract available


  62. BALSAS P, Palomero J, Eguileor A, Rodriguez ML, et al
    SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
    Blood. 2017 May 22. pii: blood-2017-04-776740. doi: 10.1182/blood-2017-04-776740
    PubMed     Text format     Abstract available


  63. FANALE MA, Cheah CY, Rich A, Medeiros LJ, et al
    Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma.
    Blood. 2017 May 18. pii: blood-2017-02-766121. doi: 10.1182/blood-2017-02-766121
    PubMed     Text format     Abstract available


  64. PEDERSEN MB, Hamilton-Dutoit SJ, Bendix K, Ketterling RP, et al
    DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study.
    Blood. 2017 May 18. pii: blood-2016-12-755496. doi: 10.1182/blood-2016-12-755496
    PubMed     Text format    


  65. KATSUYA H, Shimokawa M, Ishitsuka K, Kawai K, et al
    A prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.
    Blood. 2017 May 17. pii: blood-2017-01-757542. doi: 10.1182/blood-2017-01-757542
    PubMed     Text format     Abstract available


  66. WANG HY, Hodkoff A
    Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology.
    Blood. 2017;129:2711.
    PubMed     Text format    


  67. TOUT M, Casasnovas O, Meignan M, Lamy T, et al
    Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.
    Blood. 2017;129:2616-2623.
    PubMed     Text format     Abstract available


  68. ZINZANI PL, Ribrag V, Moskowitz CH, Michot JM, et al
    Safety & tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
    Blood. 2017 May 10. pii: blood-2016-12-758383. doi: 10.1182/blood-2016-12-758383
    PubMed     Text format     Abstract available


  69. XU J, Li S
    Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia.
    Blood. 2017;129:2593.
    PubMed     Text format    


  70. WANG HY
    Large B-cell lymphoma variant of Richter transformation originates in pseudoproliferation centers of small lymphocytic lymphoma.
    Blood. 2017;129:2592.
    PubMed     Text format    


  71. HAVERKOS BM, Abbott D, Hamadani M, Armand P, et al
    PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
    Blood. 2017 May 3. pii: blood-2017-01-761346. doi: 10.1182/blood-2017-01-761346.
    PubMed     Text format     Abstract available


  72. KURUVILLA J, Savona M, Baz R, Mau-Sorensen M, et al
    Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin's lymphoma.
    Blood. 2017 May 3. pii: blood-2016-11-750174. doi: 10.1182/blood-2016-11-750174.
    PubMed     Text format     Abstract available


    April 2017
  73. JACCARD A, Hermine O
    A major turning point in NK/T-cell lymphoma?
    Blood. 2017;129:2342-2343.
    PubMed     Text format    


  74. BUJISIC B, De Gassart A, Tallant R, Demaria O, et al
    Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.
    Blood. 2017;129:2420-2428.
    PubMed     Text format     Abstract available



  75. Risk of heart failure following Hodgkin lymphoma.
    Blood. 2017;129:2334.
    PubMed     Text format    


  76. BHATT S, Parvin S, Zhang Y, Cho HM, et al
    Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.
    Blood. 2017;129:2246-2256.
    PubMed     Text format     Abstract available


  77. DING W, LaPlant BR, Call TG, Parikh SA, et al
    Pembrolizumab in patients with chronic lymphocytic leukemia with Richter's transformation and relapsed CLL.
    Blood. 2017 Apr 19. pii: blood-2017-02-765685. doi: 10.1182/blood-2017-02-765685
    PubMed     Text format     Abstract available


  78. LE GOUILL S, Casasnovas RO
    Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: Do we trust the driver?
    Blood. 2017 Apr 17. pii: blood-2016-05-672196. doi: 10.1182/blood-2016-05-672196
    PubMed     Text format     Abstract available


  79. KRIDEL R, Sehn LH, Gascoyne RD
    Can histologic transformation of follicular lymphoma be predicted and prevented?
    Blood. 2017 Apr 13. pii: blood-2017-03-691345. doi: 10.1182/blood-2017-03-691345
    PubMed     Text format     Abstract available


  80. MILLER HK, Santo L, Camargo MC, Winkler CA, et al
    Coxiella burnetii antibody seropositivity is not a risk factor for AIDS-related non-Hodgkin lymphoma.
    Blood. 2017 Apr 10. pii: blood-2016-12-756569. doi: 10.1182/blood-2016-12-756569
    PubMed     Text format    


  81. KAKKASSERY V, Schroers R, Coupland SE, Wunderlich MI, et al
    Vitreous microRNA levels as diagnostic biomarkers for vitreo-retinal lymphoma.
    Blood. 2017 Apr 7. pii: blood-2017-01-765180. doi: 10.1182/blood-2017-01-765180.
    PubMed     Text format    


    March 2017
  82. KAWASAKI K, Karube K
    Peripheral T-cell lymphoma with EBV-infected "anaplastic" B-cell proliferation confined to sinuses.
    Blood. 2017;129:1885.
    PubMed     Text format    


  83. ALINARI L
    Toward autophagy-targeted therapy in lymphoma.
    Blood. 2017;129:1740-1742.
    PubMed     Text format    


  84. NAYAK L, Iwamoto FM, LaCasce A, Mukundan S, et al
    PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
    Blood. 2017 Mar 29. pii: blood-2017-01-764209. doi: 10.1182/blood-2017-01-764209
    PubMed     Text format     Abstract available


  85. ENNISHI D, Mottok A, Ben-Neriah S, Shulha HP, et al
    Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell of origin-specific clinical impact.
    Blood. 2017 Mar 28. pii: blood-2016-11-747022. doi: 10.1182/blood-2016-11-747022
    PubMed     Text format     Abstract available


  86. GOPAL AK, Kahl BS, Flowers CR, Martin P, et al
    Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.
    Blood. 2017 Mar 21. pii: blood-2016-12-757740. doi: 10.1182/blood-2016-12-757740
    PubMed     Text format    


  87. GARCIA-RAMIREZ I, Tadros S, Gonzalez-Herrero I, Martin-Lorenzo A, et al
    Crebbp loss cooperates with Bcl2 over-expression to promote lymphoma in mice.
    Blood. 2017 Mar 13. pii: blood-2016-08-733469. doi: 10.1182/blood-2016-08-733469
    PubMed     Text format     Abstract available


  88. WANG HY, Thorson JA
    A CD34-negative MYC-rearranged B-lymphoblastic lymphoma aberrantly expresses CD3 and CD5.
    Blood. 2017;129:1403.
    PubMed     Text format    


  89. JAHN L, Hombrink P, Hagedoorn RS, Kester MG, et al
    TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
    Blood. 2017;129:1284-1295.
    PubMed     Text format     Abstract available


  90. HERBAUX C, Gauthier J, Brice P, Drumez E, et al
    Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin's lymphoma.
    Blood. 2017 Mar 7. pii: blood-2016-11-749556. doi: 10.1182/blood-2016-11-749556.
    PubMed     Text format     Abstract available


  91. ZINZANI PL, Pellegrini C, Chiappella A, Di Rocco A, et al
    Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial.
    Blood. 2017 Mar 6. pii: blood-2017-01-764258. doi: 10.1182/blood-2017-01-764258.
    PubMed     Text format    


    February 2017
  92. PANDEY S, Mourcin F, Marchand T, Nayar S, et al
    IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma.
    Blood. 2017 Feb 15. pii: blood-2016-08-737239. doi: 10.1182/blood-2016-08-737239
    PubMed     Text format     Abstract available


  93. KWONG YL, Chan TS, Tan D, Kim SJ, et al
    PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase.
    Blood. 2017 Feb 10. pii: blood-2016-12-756841. doi: 10.1182/blood-2016-12-756841
    PubMed     Text format     Abstract available


  94. BARTOLOME-IZQUIERDO N, de Yebenes VG, Alvarez-Prado AF, Mur SM, et al
    miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma.
    Blood. 2017 Feb 10. pii: blood-2016-08-731166. doi: 10.1182/blood-2016-08-731166
    PubMed     Text format     Abstract available


  95. NGUYEN HL, Kelley TW
    T-cell rosettes in nodular lymphocyte-predominant Hodgkin lymphoma.
    Blood. 2017;129:802.
    PubMed     Text format    


  96. MYKLEBUST JH, Brody J, Kohrt HE, Kolstad A, et al
    Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Blood. 2017;129:759-770.
    PubMed     Text format     Abstract available


  97. NOY A, de Vos S, Thieblemont C, Martin P, et al
    Targeting BTK with ibrutinib in relapsed/refractory marginal zone lymphoma.
    Blood. 2017 Feb 6. pii: blood-2016-10-747345. doi: 10.1182/blood-2016-10-747345.
    PubMed     Text format     Abstract available


    January 2017
  98. VAN NIMWEGEN FA, Ntentas G, Darby SC, Schaapveld M, et al
    Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.
    Blood. 2017 Jan 31. pii: blood-2016-09-740332. doi: 10.1182/blood-2016-09-740332
    PubMed     Text format     Abstract available


  99. BROCCOLI A, Zinzani PL
    Peripheral T-cell lymphoma, not otherwise specified.
    Blood. 2017 Jan 23. pii: blood-2016-08-692566. doi: 10.1182/blood-2016-08-692566
    PubMed     Text format     Abstract available


  100. LUNNING MA, Vose JM
    Angioimmunoblastic T-cell lymphoma: the many faced lymphoma.
    Blood. 2017 Jan 23. pii: blood-2016-09-692541. doi: 10.1182/blood-2016-09-692541
    PubMed     Text format     Abstract available


  101. GAYLE S, Landrette S, Beeharry N, Conrad C, et al
    Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.
    Blood. 2017 Jan 19. pii: blood-2016-09-736892. doi: 10.1182/blood-2016-09-736892
    PubMed     Text format     Abstract available


  102. ALI ND, Weissmann D
    Charcot-Leyden crystals in T-cell lymphoblastic lymphoma.
    Blood. 2017;129:394.
    PubMed     Text format    


  103. SESQUES P, Johnson NA
    Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.
    Blood. 2017;129:280-288.
    PubMed     Text format     Abstract available


  104. MUCHTAR E, Magen H, Gertz MA
    How I treat cryoglobulinemia.
    Blood. 2017;129:289-298.
    PubMed     Text format     Abstract available


  105. ROSSI D, Diop F, Spaccarotella E, Monti S, et al
    Diffuse large B-cell lymphoma genotyping on the liquid biopsy.
    Blood. 2017 Jan 17. pii: blood-2016-05-719641. doi: 10.1182/blood-2016-05-719641
    PubMed     Text format     Abstract available


  106. ZAHN M, Marienfeld R, Melzner I, Heinrich J, et al
    A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin's lymphoma cells.
    Blood. 2017 Jan 12. pii: blood-2016-06-720516. doi: 10.1182/blood-2016-06-720516
    PubMed     Text format     Abstract available


  107. KUO SH, Chen LT, Lin CW, Yeh KH, et al
    Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL.
    Blood. 2017;129:188-198.
    PubMed     Text format     Abstract available


  108. MERRYMAN RW, Kim HT, Zinzani PL, Carlo-Stella C, et al
    Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant After PD-1 Blockade in Relapsed/Refractory Lymphoma.
    Blood. 2017 Jan 10. pii: blood-2016-09-738385. doi: 10.1182/blood-2016-09-738385
    PubMed     Text format     Abstract available


  109. CURIEL-OLMO S, Mondejar R, Almaraz C, Mollejo M, et al
    Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin.
    Blood. 2017 Jan 9. pii: blood-2016-11-751024. doi: 10.1182/blood-2016-11-751024.
    PubMed     Text format    


    December 2016
  110. LOGHAVI S, Medeiros LJ
    A rare histologic variant of a common lymphoma.
    Blood. 2016;128:3012.
    PubMed     Text format    


  111. FODERARO AE, Reagan JL
    Hodgkin lymphoma mimicking lung abscess.
    Blood. 2016;128:3011.
    PubMed     Text format    


  112. NISS ARFELT K, Barington L, Benned-Jensen T, Kubale V, et al
    EBI2 overexpression in mice leads to B1 B cell expansion and chronic lymphocytic leukemia-(CLL)-like B cell malignancies.
    Blood. 2016 Dec 21. pii: blood-2016-02-697185. doi: 10.1182/blood-2016-02-697185
    PubMed     Text format     Abstract available


  113. COHEN JB, Behera M, Thompson CA, Flowers CR, et al
    Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Blood. 2016 Dec 12. pii: blood-2016-08-685073.
    PubMed     Text format     Abstract available


    November 2016
  114. CONNORS JM
    Is the lymphoma better? Not easy to determine.
    Blood. 2016;128:2481-2482.
    PubMed     Text format    


  115. WERNER MT, Zhao C, Zhang Q, Wasik MA, et al
    Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK): the ultimate oncogene and therapeutic target.
    Blood. 2016 Nov 22. pii: blood-2016-05-717793.
    PubMed     Text format     Abstract available


  116. KIESEWETTER B, Willenbacher E, Willenbacher W, Egle A, et al
    A phase II study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma).
    Blood. 2016 Nov 22. pii: blood-2016-06-720599.
    PubMed     Text format     Abstract available


  117. DAI B, Grau M, Juilland M, Klener P, et al
    B-cell receptor driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.
    Blood. 2016 Nov 18. pii: blood-2016-05-718775.
    PubMed     Text format     Abstract available


  118. WALTER R, Pan KT, Doebele C, Comoglio F, et al
    HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B cell receptor signaling.
    Blood. 2016 Nov 15. pii: blood-2016-06-721423. doi: 10.1182/blood-2016-06-721423
    PubMed     Text format     Abstract available


  119. KRYSIAK K, Gomez F, White BS, Matlock M, et al
    Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.
    Blood. 2016 Nov 14. pii: blood-2016-07-729954. doi: 10.1182/blood-2016-07-729954
    PubMed     Text format     Abstract available


  120. NEFF JL, Chen D
    Hepatosplenic T-cell lymphoma with blastoid morphology in a patient with Crohn disease.
    Blood. 2016;128:2275.
    PubMed     Text format    


  121. MATSUSHITA H, Maruyama D
    Bone marrow involvement of primary cutaneous gamma/delta T-cell lymphoma.
    Blood. 2016;128:2274.
    PubMed     Text format    


    October 2016
  122. DESAI A, Joag MG, Lekakis L, Chapman JR, et al
    Long term course of patients with primary ocular adnexal malt lymphoma: a large single institution cohort study.
    Blood. 2016 Oct 27. pii: blood-2016-05-714584.
    PubMed     Text format     Abstract available


  123. XU-MONETTE ZY, Li L, Byrd JC, Jabbar KJ, et al
    Assessment of CD37 B-cell antigen and cell-of-origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Blood. 2016 Oct 19. pii: blood-2016-05-715094.
    PubMed     Text format     Abstract available


  124. JACOBSON C, Kopp N, Layer JV, Redd RA, et al
    HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
    Blood. 2016 Oct 14. pii: blood-2016-04-711176.
    PubMed     Text format     Abstract available


  125. DU J, Neuenschwander M, Yu Y, Dabritz JH, et al
    Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin's lymphoma.
    Blood. 2016 Oct 12. pii: blood-2016-02-700773.
    PubMed     Text format     Abstract available


  126. CHIRON D, Bellanger C, Papin A, Tessoulin B, et al
    Microenvironment-dependent proliferation and mitochondrial priming loss in mantle cell lymphoma is overcome by anti-CD20.
    Blood. 2016 Oct 3. pii: blood-2016-06-720490.
    PubMed     Text format     Abstract available


  127. UJJANI CS, Jung SH, Pitcher B, Martin P, et al
    Phase I trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
    Blood. 2016 Oct 3. pii: blood-2016-06-718106.
    PubMed     Text format     Abstract available


    September 2016

  128. Sun B, Shah B, Fiskus W, et al. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015;126(13):1565-1574.
    Blood. 2016;128:1778.
    PubMed     Text format    


  129. MANSOURI L, Noerenberg D, Young E, Mylonas E, et al
    Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.
    Blood. 2016 Sep 26. pii: blood-2016-03-704528.
    PubMed     Text format     Abstract available


  130. AMBINDER RF
    EBV, an inhibited receptor kinase, and lymphoma.
    Blood. 2016;128:1542-3.
    PubMed     Text format    


  131. OKAMURA I, Ikeda T
    Epstein-Barr virus associated with a lymphoma-mimicking lesion of the uterine cervix.
    Blood. 2016;128:1439.
    PubMed     Text format    


  132. ARCAINI L, Besson C, Frigeni M, Fontaine H, et al
    Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
    Blood. 2016 Sep 7. pii: blood-2016-05-714667.
    PubMed     Text format     Abstract available


  133. LIM MS
    Targetable gene fusions in T-cell lymphoma.
    Blood. 2016;128:1161-2.
    PubMed     Text format    


    August 2016
  134. CHESON BD, Ansell S, Schwartz L, Gordon LI, et al
    Refinement of the Lugano classification response criteria for lymphoma in the era of immunomodulatory therapy.
    Blood. 2016 Aug 29. pii: blood-2016-05-718528.
    PubMed     Text format     Abstract available


  135. REZVANI AR
    A new standard for HIV-associated lymphoma.
    Blood. 2016;128:1026-7.
    PubMed     Text format    


    July 2016
  136. KUMAR A, Casulo C, Yahalom J, Schoder H, et al
    Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
    Blood. 2016 Jul 25. pii: blood-2016-03-703470.
    PubMed     Text format     Abstract available


  137. CHEN R, Gopal AK, Smith SE, Ansell SM, et al
    Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
    Blood. 2016 Jul 18. pii: blood-2016-02-699850.
    PubMed     Text format     Abstract available


  138. JURINOVIC V, Kridel R, Staiger AM, Szczepanowski M, et al
    Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
    Blood. 2016 Jul 14. pii: blood-2016-05-717355.
    PubMed     Text format     Abstract available


  139. MIYOSHI H, Kiyasu J, Kato T, Yoshida N, et al
    PD-L1 expression on neoplastic or stromal cell is respectively poor or good prognostic factor for adult T-cell leukemia/lymphoma.
    Blood. 2016 Jul 14. pii: blood-2016-02-698936.
    PubMed     Text format     Abstract available


    June 2016
  140. MOIZ B, Majeed A
    Gray-zone lymphoma: a complex reality.
    Blood. 2016;127:3459.
    PubMed     Text format    


  141. ALBERTSSON-LINDBLAD A, Kolstad A, Laurell A, Raty R, et al
    Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4.
    Blood. 2016 Jun 27. pii: blood-2016-03-704023.
    PubMed     Text format     Abstract available


  142. HUANG YC, Lin SJ, Lin KM, Chou YC, et al
    Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival.
    Blood. 2016 Jun 23. pii: blood-2016-02-702530.
    PubMed     Text format     Abstract available


  143. LYNCH DT, Foucar K
    Discrete vacuoles in lymphocytes as a subtle clue to mantle cell lymphoma.
    Blood. 2016;127:3292.
    PubMed     Text format    


  144. SPINA V, Khiabanian H, Messina M, Monti S, et al
    The genetics of nodal marginal zone lymphoma.
    Blood. 2016 Jun 22. pii: blood-2016-02-696757.
    PubMed     Text format     Abstract available


  145. LOUISSAINT A JR, Schafernak KT, Geyer J, Kovach AE, et al
    Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAP kinase pathway mutations.
    Blood. 2016 Jun 20. pii: blood-2015-12-682591.
    PubMed     Text format     Abstract available


  146. BHATTI R, Aguilera NS
    Reverse variant of follicular lymphoma: uncommon morphology in a common lymphoma.
    Blood. 2016;127:3103.
    PubMed     Text format    


  147. WANG HY, Wang L
    Diagnostic pitfall: primary effusion lymphoma with rare cytokeratin immunoreactivity.
    Blood. 2016;127:3102.
    PubMed     Text format    


  148. BODDICKER RL, Razidlo GL, Dasari S, Zeng Y, et al
    Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.
    Blood. 2016 Jun 13. pii: blood-2016-03-707141.
    PubMed     Text format     Abstract available


  149. ALVARNAS JC, Le Rademacher J, Wang Y, Little RF, et al
    Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the (BMT CTN) 0803/(AMC) 071 Trial.
    Blood. 2016 Jun 13. pii: blood-2015-08-664706.
    PubMed     Text format     Abstract available


  150. YAN J, Li B, Lin B, Lee PT, et al
    EZH2 phosphorylation by JAK3 mediates a switch to non-canonical function in natural killer/T-cell lymphoma.
    Blood. 2016 Jun 13. pii: blood-2016-01-690701.
    PubMed     Text format     Abstract available


  151. PRATT D, Uldrick TS
    Primary effusion lymphoma and concurrent progressive Kaposi sarcoma associated with elevated interleukin-6.
    Blood. 2016;127:2940.
    PubMed     Text format    


  152. DIAZ-CRESPO F, Mollejo M
    Intravascular large B-cell lymphoma in a kidney biopsy.
    Blood. 2016;127:2939.
    PubMed     Text format    


  153. SCHMIDT J, Gong S, Marafioti T, Mankel B, et al
    Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene.
    Blood. 2016 Jun 2. pii: blood-2016-03-703819.
    PubMed     Text format     Abstract available


  154. CHEAH CY, Fowler NH
    Idelalisib in the management of lymphoma.
    Blood. 2016 Jun 1. pii: blood-2016-02-702761.
    PubMed     Text format     Abstract available


    May 2016
  155. CHESON BD
    Speed bumps on the road to a chemotherapy-free world for lymphoma patients.
    Blood. 2016 May 24. pii: blood-2016-04-709477.
    PubMed     Text format     Abstract available


  156. KASENDA B, Loeffler J, Illerhaus G, Ferreri AJ, et al
    The role of whole brain radiation in primary CNS lymphoma.
    Blood. 2016 May 13. pii: blood-2016-01-650101.
    PubMed     Text format     Abstract available


  157. ASSOULINE SE, Nielsen TH, Yu S, Alcaide M, et al
    Phase 2 study of panobinostat +/- rituximab in relapsed diffuse large B cell lymphoma and biomarkers predictive of response.
    Blood. 2016 May 10. pii: blood-2016-02-699520.
    PubMed     Text format     Abstract available


  158. MATTHEWS JM, Bhatt S, Patricelli MP, Nomanbhoy TK, et al
    Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma.
    Blood. 2016 May 5. pii: blood-2016-02-696856.
    PubMed     Text format     Abstract available


    April 2016
  159. SABA NS, Liu D, Herman SE, Underbayev C, et al
    Pathogenic role of B-cell receptor signaling and canonical NF-kappaB activation in mantle cell lymphoma.
    Blood. 2016 Apr 28. pii: blood-2015-11-681460.
    PubMed     Text format     Abstract available


  160. KOTSIOU E, Okosun J, Besley C, Iqbal S, et al
    TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses.
    Blood. 2016 Apr 21. pii: blood-2015-10-679191.
    PubMed     Text format     Abstract available


  161. LI W, Repnikova E
    ALK-positive anaplastic large-cell lymphoma with marked leukemoid reaction and hemophagocytic lymphohistiocytosis.
    Blood. 2016;127:2041.
    PubMed     Text format    


  162. FANALE M
    New insights into NLPHL transformation.
    Blood. 2016;127:1946-7.
    PubMed     Text format    


  163. ROSCHEWSKI M, Staudt LM, Wilson WH
    Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma.
    Blood. 2016 Apr 14. pii: blood-2016-03-635219.
    PubMed     Text format     Abstract available



  164. McFarland W, Granville NB, Dameshek W. Autologous bone marrow infusion as an adjunct in therapy of malignant disease. Blood. 1959;14(5):503-521.
    Blood. 2016;127:1839.
    PubMed     Text format     Abstract available


  165. BLONSKA M
    ATF3, a new player in DLBCL cell survival.
    Blood. 2016;127:1736-7.
    PubMed     Text format     Abstract available


  166. JUILLAND M, Gonzalez M, Erdmann T, Banz Y, et al
    CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.
    Blood. 2016;127:1780-9.
    PubMed     Text format     Abstract available


  167. KNITTEL G, Liedgens P, Korovkina D, Seeger JM, et al
    B cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B cell lymphoma in mice.
    Blood. 2016 Apr 5. pii: blood-2015-11-684183.
    PubMed     Text format     Abstract available


    March 2016
  168. ZIJLSTRA JM
    PET-CT: reliable cornerstone for Hodgkin lymphoma treatment?
    Blood. 2016;127:1521-2.
    PubMed     Text format    


  169. PAGANO JS, Shackelford J
    UCH-L1 in DLBCL: marker or target?
    Blood. 2016;127:1524-5.
    PubMed     Text format     Abstract available


  170. SMITH MR
    Ibrutinib: a force with a dark side?
    Blood. 2016;127:1523-4.
    PubMed     Text format     Abstract available


  171. ARMITAGE JO, Longo DL
    Is watch and wait still acceptable for patients with low grade follicular lymphoma?
    Blood. 2016 Mar 18. pii: blood-2015-11-632745.
    PubMed     Text format     Abstract available


  172. ARCAINI L, Rossi D, Paulli M
    Splenic marginal zone lymphoma: from genetics to management.
    Blood. 2016 Mar 17. pii: blood-2015-11-624312.
    PubMed     Text format     Abstract available


  173. KURUVILLA J
    The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma.
    Blood. 2016 Mar 17. pii: blood-2015-11-624320.
    PubMed     Text format     Abstract available


  174. ZUCCA E, Bertoni F
    The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance.
    Blood. 2016 Mar 17. pii: blood-2015-12-624304.
    PubMed     Text format     Abstract available


  175. KAHL BS, Yang D
    Follicular lymphoma: evolving therapeutic strategies.
    Blood. 2016 Mar 17. pii: blood-2015-11-624288.
    PubMed     Text format     Abstract available


  176. THIEBLEMONT C, Molina T, Davi F
    Optimizing therapy for nodal marginal zone lymphoma.
    Blood. 2016 Mar 17. pii: blood-2015-12-624296.
    PubMed     Text format     Abstract available


  177. HEALY JA, Nugent A, Rempel RE, Moffitt AB, et al
    GNA13 loss in germinal center B cells leads to impaired apoptosis and GC B cell persistence and promotes lymphoma in vivo.
    Blood. 2016 Mar 17. pii: blood-2015-07-659938.
    PubMed     Text format     Abstract available


  178. MASKOVYAK AE, Nakashima MO
    Circulating CD30-positive T-cell lymphoma with anaplastic morphology.
    Blood. 2016;127:1516.
    PubMed     Text format    


  179. BALDARI CT
    S1PR2 deficiency in DLBCL: a FOXy connection.
    Blood. 2016;127:1380-1.
    PubMed     Text format     Abstract available


  180. CHOUDHARI R, Minero VG, Menotti M, Pulito R, et al
    Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice.
    Blood. 2016;127:1297-306.
    PubMed     Text format     Abstract available


  181. KOZLOSKI GA, Jiang X, Bhatt S, Ruiz J, et al
    MiR-181a negatively regulates NF-kappaB signaling and affects activated B-cell like diffuse large B-cell lymphoma pathogenesis.
    Blood. 2016 Mar 3. pii: blood-2015-11-680462.
    PubMed     Text format     Abstract available


    February 2016
  182. CHEN Z, Hu S
    MYC/BCL2 double-hit lymphoma/leukemia mimicking acute leukemia at initial presentation.
    Blood. 2016;127:1072.
    PubMed     Text format    


  183. YEOMANS A, Packham G
    Shooting the messenger (RNA) in B-cell lymphoma.
    Blood. 2016;127:794-6.
    PubMed     Text format    


  184. DUROT E, Patey M
    Pure red cell aplasia revealing nonnodal mantle cell lymphoma.
    Blood. 2016;127:952.
    PubMed     Text format    


  185. KANAKRY JA, Luznik L
    Might haplo "be the (better) match"?
    Blood. 2016;127:799-800.
    PubMed     Text format    


  186. CHAPUY B, Roemer MG, Stewart C, Tan Y, et al
    Targetable genetic features of primary testicular and primary central nervous system lymphomas.
    Blood. 2016;127:869-81.
    PubMed     Text format     Abstract available


  187. KANATE AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, et al
    Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.
    Blood. 2016;127:938-47.
    PubMed     Text format     Abstract available


  188. CULJKOVIC-KRALJACIC B, Fernando TM, Marullo R, Calvo-Vidal N, et al
    Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.
    Blood. 2016;127:858-68.
    PubMed     Text format     Abstract available


  189. LYKKEN JM, Horikawa M, Minard-Colin V, Kamata M, et al
    Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms.
    Blood. 2016 Feb 17. pii: blood-2015-11-681130.
    PubMed     Text format     Abstract available


  190. SZYDLOWSKI M, Kiliszek P, Sewastianik T, Jablonska E, et al
    FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
    Blood. 2016;127:739-48.
    PubMed     Text format     Abstract available


  191. EFREMOV DG
    FOXO discriminates tonic from chronic in DLBCL.
    Blood. 2016;127:669-70.
    PubMed     Text format    


  192. KENDERIAN SS, Habermann TM, Macon WR, Ristow KM, et al
    Large B-cell transformation in nodular lymphocyte predominant Hodgkin lymphoma: forty-year experience from a single institution.
    Blood. 2016 Feb 2. pii: blood-2015-08-665505.
    PubMed     Text format     Abstract available


  193. FERRERI AJ, Illerhaus G
    The role of autologous stem cell transplantation in primary CNS lymphoma.
    Blood. 2016 Feb 1. pii: blood-2015-10-636340.
    PubMed     Text format     Abstract available


  194. BOLL B, Goergen H, Behringer K, Brockelmann PJ, et al
    Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.
    Blood. 2016 Feb 1. pii: blood-2015-11-681064.
    PubMed     Text format     Abstract available


    January 2016
  195. WALTER HS, Rule SA, Dyer MJ, Karlin L, et al
    A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
    Blood. 2016;127:411-9.
    PubMed     Text format     Abstract available


  196. CHAPUY B, Cheng H, Watahiki A, Ducar MD, et al
    Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biologic heterogeneity of the disease.
    Blood. 2016 Jan 15. pii: blood-2015-09-672352.
    PubMed     Text format     Abstract available


  197. MIRANTES C, Dosil MA, Hills D, Yang J, et al
    Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma, but not myeloid malignancies.
    Blood. 2016 Jan 14. pii: blood-2015-09-669036.
    PubMed     Text format     Abstract available


  198. GAULARD P, de Leval L
    ALK-negative anaplastic large-cell lymphoma.
    Blood. 2016;127:175-7.
    PubMed     Text format    


  199. ARNOUX I, Loosveld M
    Hepatosplenic T-cell lymphoma: an acute leukemia presentation.
    Blood. 2016;127:269.
    PubMed     Text format    


  200. KING RL, Howard MT
    Lymphocytic variant of hypereosinophilic syndrome mimicking peripheral T-cell lymphoma in a young woman.
    Blood. 2016;127:268.
    PubMed     Text format    


  201. SCARFO I, Pellegrino E, Mereu E, Kwee I, et al
    Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts.
    Blood. 2016;127:221-32.
    PubMed     Text format     Abstract available


  202. DOLCETTI R, Gloghini A, Caruso A, Carbone A, et al
    A lymphomagenic role for HIV beyond immune suppression?
    Blood. 2016 Jan 14. pii: blood-2015-11-681411.
    PubMed     Text format     Abstract available


  203. MARTIN P, Maddocks K, Leonard JP, Ruan J, et al
    Post-ibrutinib outcomes in patients with mantle cell lymphoma.
    Blood. 2016 Jan 13. pii: blood-2015-10-673145.
    PubMed     Text format     Abstract available


  204. VIARDOT A, Goebeler ME, Hess G, Neumann S, et al
    Phase 2 study of bispecific T-cell engager (BiTE(R)) antibody blinatumomab in relapsed/refractory diffuse large B cell lymphoma.
    Blood. 2016 Jan 11. pii: blood-2015-06-651380.
    PubMed     Text format     Abstract available


  205. JAIN N, Lamb AE, O'Brien S, Ravandi F, et al
    Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.
    Blood. 2016 Jan 8. pii: blood-2015-08-661702.
    PubMed     Text format     Abstract available


  206. BARRINGTON SF, Kirkwood AA, Franceschetto A, Fulham MJ, et al
    PET-CT for staging & early response: results from 'Response Adapted Therapy in Advanced Hodgkin Lymphoma' (RATHL) (CRUK/07/033).
    Blood. 2016 Jan 8. pii: blood-2015-11-679407.
    PubMed     Text format     Abstract available


  207. FLOWERS CR, Skibola CF
    Identifying risk factors for B-cell lymphoma.
    Blood. 2016;127:10-1.
    PubMed     Text format    


  208. WILLERSLEV-OLSEN A, Krejsgaard T, Lindahl LM, Litvinov IV, et al
    Staphylococcus aureus enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.
    Blood. 2016 Jan 5. pii: blood-2015-08-662353.
    PubMed     Text format     Abstract available


  209. FLORI M, Schmid CA, Sumrall ET, Tzankov A, et al
    The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.
    Blood. 2016 Jan 4. pii: blood-2015-08-662635.
    PubMed     Text format     Abstract available


    December 2015
  210. RADFORD J
    Treatment of Hodgkin lymphoma in older patients.
    Blood. 2015;126:2768-9.
    PubMed     Text format    


  211. BEDEKOVICS T, Hussain S, Feldman AL, Galardy PJ, et al
    UCH-L1 is induced in germinal center B-cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
    Blood. 2015 Dec 23. pii: blood-2015-07-656678.
    PubMed     Text format     Abstract available


  212. BRUDNO J, Tadmor T, Pittaluga S, Nicolae A, et al
    Discordant bone marrow involvement in non-Hodgkin lymphoma.
    Blood. 2015 Dec 17. pii: blood-2015-06-651968.
    PubMed     Text format     Abstract available


  213. CZUCZMAN NM, Barth MJ, Gu J, Neppalli V, et al
    Pevonedistat, a NEDD8 activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
    Blood. 2015 Dec 16. pii: blood-2015-04-640920.
    PubMed     Text format     Abstract available


    November 2015
  214. CHOI SM, Chen YH
    Primary effusion lymphoma.
    Blood. 2015;126:2522.
    PubMed     Text format    


  215. COPIE-BERGMAN C, Cuilliere-Dartigues P, Baia M, Briere J, et al
    MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
    Blood. 2015;126:2466-74.
    PubMed     Text format     Abstract available


  216. CAMPO E
    MYC in DLBCL: partners matter.
    Blood. 2015;126:2439-40.
    PubMed     Text format     Abstract available


  217. AGARWAL NK, Kim CH, Kunkalla K, Konno H, et al
    Active IKKbeta promotes the stability of GLI1 oncogene in diffuse large B-cell lymphoma.
    Blood. 2015 Nov 24. pii: blood-2015-07-658781.
    PubMed     Text format     Abstract available


  218. MATTHEWS GM, Mehdipour P, Cluse LA, Falkenberg KJ, et al
    Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
    Blood. 2015;126:2392-403.
    PubMed     Text format     Abstract available


  219. KELLY KM
    Hodgkin lymphoma in children and adolescents: improving the therapeutic index.
    Blood. 2015 Nov 18. pii: blood-2015-07-641035.
    PubMed     Text format     Abstract available


  220. ALINARI L, Blum KA
    How I treat relapsed classical Hodgkin Lymphoma after autologous stem cell transplant.
    Blood. 2015 Nov 17. pii: blood-2015-10-671826.
    PubMed     Text format     Abstract available


  221. NAGATA Y, Kontani K, Enami T, Kataoka K, et al
    Variegated RHOA mutations in adult T-cell leukemia/lymphoma.
    Blood. 2015 Nov 16. pii: blood-2015-06-644948.
    PubMed     Text format     Abstract available


  222. ARANGO M
    Adult T-cell leukemia/lymphoma.
    Blood. 2015;126:2343.
    PubMed     Text format    


  223. BENEDICT M, Hudnall D
    Lymphoplasmacytic lymphoma with prominent mast cell infiltrates.
    Blood. 2015;126:2342.
    PubMed     Text format    


  224. HATHCOCK KS, Padilla-Nash HM, Camps J, Shin DM, et al
    ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans.
    Blood. 2015;126:2291-301.
    PubMed     Text format     Abstract available


  225. DIERICKX D, Tousseyn T, Gheysens O
    How I treat posttransplant lymphoproliferative disorders.
    Blood. 2015;126:2274-83.
    PubMed     Text format     Abstract available


  226. BOUSSIOTIS VA
    Cell-specific PD-L1 expression in DLBCL.
    Blood. 2015;126:2171-2.
    PubMed     Text format    


    October 2015
  227. BENAYOUN E, Wagner-Ballon O
    Hepatosplenic T-cell lymphoma mimicking bone marrow metastasis.
    Blood. 2015;126:2071.
    PubMed     Text format    


  228. DEBORD C, Eveillard M
    Leukemic phase of a large B-cell lymphoma arising in KSHV-associated multicentric Castleman disease.
    Blood. 2015;126:1966.
    PubMed     Text format    


  229. OFFNER F, Samoilova O, Osmanov E, Eom HS, et al
    Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.
    Blood. 2015;126:1893-901.
    PubMed     Text format     Abstract available


  230. KHAN N, Fisher RI
    Subtype-specific therapy for DLBCL: are we there yet?
    Blood. 2015;126:1869-70.
    PubMed     Text format     Abstract available


  231. WANG HY, Thorson JA
    T-cell primary effusion lymphoma with pseudo-monoclonal rearrangements for immunoglobulin heavy chain.
    Blood. 2015;126:1856.
    PubMed     Text format    


  232. PILERI SA
    Follicular helper T-cell-related lymphomas.
    Blood. 2015;126:1733-4.
    PubMed     Text format     Abstract available


  233. MARTIN P
    Is the open mouth mightier than the needle?
    Blood. 2015;126:1638-9.
    PubMed     Text format     Abstract available


  234. LU Z, Pannunzio NR, Greisman HA, Casero D, et al
    Convergent BCL6 and lncRNA promoters demarcate the major breakpoint region for BCL6 translocations.
    Blood. 2015;126:1730-1.
    PubMed     Text format    


    September 2015
  235. KUMAR A, Puvvada S
    Mantle cell lymphoma presenting as cardiac tamponade.
    Blood. 2015;126:1255.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: